Exciting Developments in the Pipeline in HER2+ MBC
A multidisciplinary panel of health care professionals and a patient advocate comment on their excitement about novel therapies in the pipeline for HER2-positive metastatic breast cancer.
Shared Decision-Making and Treatment Sequencing in HER2+ MBC
The importance of forming partnerships with patients and understanding their preferences for therapy when establishing treatment algorithms for patients with HER2-positive metastatic breast cancer.
Treatment Strategies for HER2+ Breast Cancer and Brain Metastases
Treatment recommendations for patients with HER2-positive metastatic breast cancer, like Erika Rich, upon identification of lesions in the brain.
HER2+ MBC: Preparing Patients for Chemotherapy
Adverse events commonly associated with chemotherapies used to treat HER2-positive metastatic breast cancer, and recommendations to help equip patients with knowledge about what to expect during their treatment journey.
Pursuing a Second Opinion About HER2+ MBC Treatment
Erika Rich, a patient with HER2-positive metastatic breast cancer, explains why she opted to pursue a second opinion about her diagnosis and treatment options and proactively research her disease.
Subcutaneous Therapies for HER2+ MBC
Julia A. LaBarbera, NP, reacts to the treatment approach used for a patient with HER2-positive metastatic breast cancer, and highlights the benefits of new subcutaneous injections of trastuzumab and pertuzumab that are available.
Radiation Therapy for HER2+ De Novo MBC
Radiation oncologist Kamran Ahmed, MD, comments on indications for using radiation therapy to treat patients with HER2-positive de novo metastatic breast cancer.
Chemotherapy for HER2+ MBC
The rationale for treating Erika Rich, a patient with HER2-positive metastatic breast cancer, with docetaxel, trastuzumab, and pertuzumab.
Common Symptoms Associated With HER2+ Metastatic Breast Cancer
Patient advocate Erika Rich compares initial symptoms that prompted her to seek a medical evaluation with symptoms commonly associated with HER2-positive metastatic breast cancer.
HER2+ Metastatic Breast Cancer Treatment Advances
A discussion regarding treatment advances in HER2-positive metastatic breast cancer, a heterogeneous disease.
2 Clarke Drive Cranbury, NJ 08512